168 related articles for article (PubMed ID: 20519801)
1. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
Traina TA; Dugan U; Higgins B; Kolinsky K; Theodoulou M; Hudis CA; Norton L
Breast Dis; 2010; 31(1):7-18. PubMed ID: 20519801
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
4. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
5. Oral capecitabine (Xeloda) in cancer treatment.
Doyle DP; Engelking C
Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
[No Abstract] [Full Text] [Related]
6. Evolution of capecitabine dosing in breast cancer.
Naughton M
Clin Breast Cancer; 2010 Apr; 10(2):130-5. PubMed ID: 20299321
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine dosing is not yet optimized for breast cancer.
Hudis C; Traina T; Norton L
Ann Oncol; 2010 Nov; 21(11):2291; author reply 2291-2. PubMed ID: 20501505
[No Abstract] [Full Text] [Related]
8. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Gajria D; Feigin K; Tan LK; Patil S; Geneus S; Theodoulou M; Norton L; Hudis CA; Traina TA
Cancer; 2011 Sep; 117(18):4125-31. PubMed ID: 21387266
[TBL] [Abstract][Full Text] [Related]
10. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
[TBL] [Abstract][Full Text] [Related]
12. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
Zielinski C; Gralow J; Martin M
Ann Oncol; 2010 Nov; 21(11):2145-2152. PubMed ID: 20332132
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Yap YS; Kendall A; Walsh G; Banerji U; Johnston SR; Smith IE; O'Brien M
Breast; 2007 Aug; 16(4):420-4. PubMed ID: 17379519
[TBL] [Abstract][Full Text] [Related]
14. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Honma H
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2045-8. PubMed ID: 17197750
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Lokich J
Cancer Invest; 2004; 22(5):713-7. PubMed ID: 15581052
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
20. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Hennessy BT; Gauthier AM; Michaud LB; Hortobagyi G; Valero V
Ann Oncol; 2005 Aug; 16(8):1289-96. PubMed ID: 15890665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
